I don’t have live access to tools in this turn, but here’s a concise update based on recent public reporting. Direct answer
- Gordon Findlay, a Novo Nordisk executive, reportedly fainted during a White House Oval Office event in early November 2025 while President Trump discussed a deal related to obesity medications. Reports indicate he was attended to by medical staff and later appeared to recover, with the press conference resuming after the incident. Several outlets covered the event with varying details about his exact role and condition, but the prevailing takeaway was that he experienced a fainting episode and subsequently recovered.
Context and what to watch for
- Sources varied in emphasis, with some focusing on the medical response and others on the broader political and pharmaceutical price-news context. The incident occurred during remarks tied to GLP-1 obesity drugs, and coverage noted the press conference resumed after the interruption. If you’d like, I can pull the latest, most verified reports from major outlets to confirm current status and any official statements.
